Mankind Pharma Limited IPO Detail

Incorporated in 1991, Mankind Pharma Limited develops, manufactures, and markets pharmaceutical formulations across various acute and chronic therapeutic areas and several consumer healthcare products.

In India, the business is active in a number of acute and chronic therapeutic fields, including anti-infectives, cardiovascular, gastrointestinal, anti-diabetic, neuro/CNS, vitamins/minerals/nutrients, and respiratory.

It has over 36 brands, including Manforce (Rx), Moxikind-CV, Amlokind-AT, Unwanted-Kit, Candiforce, Gudcef, Glimestar-M, Prega News, Dydroboon, Codistar, Nurokind-Gold, Nurokind Plus-RF, Nurokind-LC, Asthakind-DX, Cefakind, Monticope, Telmikind-H, Telmikind, Gudcef-CV, and Unwanted-72, among them.

Mankind Pharma has one of the largest distribution networks of medical representatives in the Indian pharmaceutical market. Over 80% of doctors in India prescribed their formulations and has been ranked number 4th in terms of domestic sales during the Financial Year 2022.

The company has earned numerous awards and recognitions and including The Best of Bharat Awards 2022 by exchange4media in the year 2022, and Silver Medal from National Awards for Manufacturing Competitiveness Assessment 2021 instituted by International Research Institute for Manufacturing.

Mankind has a pan-India marketing presence, with a field force of 11,691 medical representatives and 3,561 field managers, as of December 31, 2022. They operate 25 manufacturing facilities across India and had 4,121 manufacturing personnel as of December 31, 2022.

As of December 31, 2022, the Company had a team of over 600 scientists and a dedicated in-house R&D center with four units located in IMT Manesar, Gurugram, Haryana and Thane, Maharashtra.

Mankind Pharma IPO Details

IPO DateApr 25, 2023 to Apr 27, 2023
Listing Date[.]
Face Value₹1 per share
Price₹1026 to ₹1080 per share
Lot Size13 Shares
Total Issue Size40,058,844 shares
(aggregating up to ₹4,326.36 Cr)
Offer for Sale40,058,844 shares of ₹1
(aggregating up to ₹4,326.36 Cr)
Issue TypeBook Built Issue IPO
Listing AtBSE, NSE

Mankind Pharma IPO Reservation

QIB Shares OfferedNot more than 50% of the Net Issue
NII (HNI) Shares OfferedNot less than 15% of the Net Issue
Retail Shares OfferedNot less than 35% of the Net Issue

Mankind Pharma IPO Tentative Timetable

Mankind Pharma IPO opens on Apr 25, 2023, and closes on Apr 27, 2023.

EventTentative Date
Opening DateApr 25, 2023
Closing DateApr 27, 2023
Basis of AllotmentMay 3, 2023
Initiation of RefundsMay 4, 2023
Credit of Shares to DematMay 5, 2023
Listing DateMay 8, 2023
UPI Mandate Confirmation Cut-Off Time5.00 PM on the issue closing day

Mankind Pharma IPO Lot Size

The Mankind Pharma IPO lot size is 13 shares.

Retail (Min)113₹14,040
Retail (Max)14182₹196,560
S-HNI (Min)15195₹210,600
S-HNI (Max)71923₹996,840
B-HNI (Min)72936₹1,010,880

Mankind Pharma IPO Promoter Holding

Ramesh Juneja, Rajeev Juneja, Sheetal Arora, Ramesh Juneja Family Trust, Rajeev Juneja Family Trust, and Prem Sheetal Family Trust are the company promoters.

Pre Issue Share Holding79.00%
Post Issue Share Holding

Company Financials(In lakh)

Period EndedTotal AssetsTotal RevenueProfit After TaxNet WorthReserves and SurplusTotal Borrowing

Key Performance Indicator

ROCE (%)16.58

Objects of the Issue

Th company will not receive any proceeds from the Offer and all the Offer Proceeds will be received by the Selling Shareholders, in proportion to the Offered Shares sold by the respective Selling Shareholders as part of the Offer

Mankind Pharma IPO Review (May apply)

[Dilip Davda]  A major domestic player in healthcare products is going public with a pure vanilla OFS issue. It is diluting just 10% now. It has shown good financial performance from FY20 to FY22. The setback for 9m of FY23 is due to one-time provisioning for its recent takeovers. Based on recent performance, the issue appears fully priced. It’s a long race horse, hence investors may consider parking funds with a long-term perspective.

Company Contact Information

Mankind Pharma Limited
208, Okhla Industrial Estate
New Delhi 110020
Phone: +91 11 4684 6700

Mankind Pharma IPO Registrar

Kfin Technologies Limited

Phone: 04067162222, 04079611000

Leave a Reply

Your email address will not be published. Required fields are marked *